Investigational drug · Phase 2
ACT-777991
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Segmental Vitiligo.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ACT-777991"
First trial start
2026
Oct 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACT-777991", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Segmental Vitiligo
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "ACT-777991" as an intervention, largest first.
Idorsia Pharmaceuticals Ltd.Industry
NCT04798209 · 70 participants · Start Jan 29, 2021 · Primary completion Jan 26, 2022
Drug: ACT-777991 (SAD); ACT-777991 (MAD) and 6 more · For: Healthy
Sites: Groningen, Netherlands
- A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental VitiligoRecruiting
Idorsia Pharmaceuticals Ltd.Industry
NCT07667569 · 30 participants (planned) · Start Oct 6, 2026 · Primary completion Jun 28, 2027
Drug: ACT-777991; Placebo · For: Non-Segmental Vitiligo
Sites: Los Angeles, California; Katowice, Poland; Krakow, Poland · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- CXCR3 inhibitors for therapeutic interventions: current status and perspectives.
Huo R, Jiang Y, Zhang L, et al. · Front Pharmacol 2025
- Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.
Boof ML, Géhin M, Voors-Pette C, et al. · Br J Clin Pharmacol 2024
- Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes.
Christen U, Pouzol L, Tunis M, et al. · Clin Exp Immunol 2023
- Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.
Meyer EA, Äänismaa P, Ertel EA, et al. · J Med Chem 2023
Also in development for Non-Segmental Vitiligo
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
- SHR0302Phase 32 trials
Jiangsu HengRui Medicine Co., Ltd. · Non-segmental Vitiligo, Psoriatic Arthritis
- GIA632Phase 23 trials
Novartis · Atopic Dermatitis, Non-segmental Vitiligo, Cutaneous Lichen Planus
- SHR0302BasePhase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Vitiligo, Non-segmental Vitiligo
- EI-001Phase 21 trial
Elixiron Immunotherapeutics (Hong Kong) Ltd. · Non-segmental Vitiligo
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.